{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:31:36Z","timestamp":1794108696900,"version":"4.8.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023QB257"],"award-info":[{"award-number":["ZR2023QB257"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2024QH006"],"award-info":[{"award-number":["ZR2024QH006"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007101","name":"Liaocheng University","doi-asserted-by":"publisher","award":["318052436"],"award-info":[{"award-number":["318052436"]}],"id":[{"id":"10.13039\/501100007101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007101","name":"Liaocheng University","doi-asserted-by":"publisher","award":["2024XT02"],"award-info":[{"award-number":["2024XT02"]}],"id":[{"id":"10.13039\/501100007101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302903"],"award-info":[{"award-number":["82302903"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400679"],"award-info":[{"award-number":["82400679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178211","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:27:18Z","timestamp":1760164038000},"page":"178211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Berberine sensitizes liver cancer cells to sorafenib by inducing SETDB1\/NQO1\/p53-dependent ferroptosis and genomic instability"],"prefix":"10.1016","volume":"1007","author":[{"given":"Kunyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178211_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173919","article-title":"Synergistic potential of dual andrographolide and melatonin targeting of metastatic colon cancer cells: using the Chou-Talalay combination index method","volume":"897","author":"Banerjee","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178211_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000531744","article-title":"Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis","volume":"13","author":"Celsa","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ejphar.2025.178211_bib3","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-22-4001","article-title":"DPP9 stabilizes NRF2 to suppress ferroptosis and induce sorafenib resistance in clear cell renal cell carcinoma","volume":"83","author":"Chang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jhep.2009.10.011","article-title":"Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation","volume":"52","author":"Chen","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2025.178211_bib5","article-title":"New insights on sorafenib resistance in liver cancer with correlation of individualized therapy","volume":"1874","author":"Cheng","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejphar.2025.178211_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1835","article-title":"Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo","volume":"10","author":"Dibra","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejphar.2025.178211_bib7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178211_bib8","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02523","article-title":"Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis","volume":"3","author":"Dixon","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.ejphar.2025.178211_bib9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/ncb3064","article-title":"Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice","volume":"16","author":"Friedmann Angeli","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178211_bib10","doi-asserted-by":"crossref","first-page":"6797","DOI":"10.1111\/jcmm.14560","article-title":"Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs","volume":"23","author":"Gao","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178211_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","article-title":"Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity","volume":"595","author":"Griffin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.178211_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117114","article-title":"Berberine ameliorates nonalcoholic fatty liver disease-induced bone loss by inhibiting ferroptosis","volume":"185","author":"Gu","year":"2024","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2025.178211_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejphar.2025.178211_bib14","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/gutjnl-2015-311292","article-title":"Epigenetics in liver disease: from biology to therapeutics","volume":"65","author":"Hardy","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178211_bib15","first-page":"20","article-title":"Berberine: a traditional natural product with novel biological activities","volume":"26","author":"Hou","year":"2020","journal-title":"Alternative Ther. Health Med."},{"key":"10.1016\/j.ejphar.2025.178211_bib16","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1002\/ptr.8255","article-title":"Berberine and berberine nanoformulations in cancer therapy: focusing on lung cancer","volume":"38","author":"Hsu","year":"2024","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib17","first-page":"1525","article-title":"Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib","volume":"40","author":"Huang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejphar.2025.178211_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"520","author":"Jiang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.178211_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178211_bib20","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/pro.3715","article-title":"Toward understanding the origin and evolution of cellular organisms","volume":"28","author":"Kanehisa","year":"2019","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejphar.2025.178211_bib21","doi-asserted-by":"crossref","first-page":"D672","DOI":"10.1093\/nar\/gkae909","article-title":"KEGG: biological systems database as a model of the real world","volume":"53","author":"Kanehisa","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/nu14173459","article-title":"Berberine in non-alcoholic fatty liver Disease-A review","volume":"14","author":"Koperska","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.ejphar.2025.178211_bib24","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejphar.2025.178211_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106306","article-title":"Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer","volume":"182","author":"Li","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41401-020-0478-3","article-title":"Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma","volume":"42","author":"Li","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2025.178211_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116832","article-title":"Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway","volume":"176","author":"Liao","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178211_bib28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/1535-7163.MCT-19-0135","article-title":"Ibrutinib potentiates antihepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma","volume":"19","author":"Lin","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2025.178211_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108593","article-title":"Berberine prevents NAFLD and HCC by modulating metabolic disorders","volume":"254","author":"Lin","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178211_bib30","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","article-title":"Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation","volume":"113","author":"Metzelder","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178211_bib31","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.21037\/tcr.2018.11.23","article-title":"The future is now: beyond first line systemic therapy in hepatocellular carcinoma","volume":"8","author":"Nenu","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41420-022-01199-8","article-title":"Mitochondrial event as an ultimate step in ferroptosis","volume":"8","author":"Oh","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejphar.2025.178211_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/921416","article-title":"Effect of Rhizoma coptidis (Huang Lian) on treating diabetes mellitus","volume":"2015","author":"Pang","year":"2015","journal-title":"Evid. Based Complement Alternat. Med."},{"key":"10.1016\/j.ejphar.2025.178211_bib34","doi-asserted-by":"crossref","first-page":"W160","DOI":"10.1093\/nar\/gkw257","article-title":"deepTools2: a next generation web server for deep-sequencing data analysis","volume":"44","author":"Ram\u00edrez","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1634\/theoncologist.2015-0055","article-title":"Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma","volume":"20","author":"Rao","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2025.178211_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237368","article-title":"Berberine as a potential anticancer agent: a comprehensive review","volume":"26","author":"Rauf","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.178211_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.leukres.2018.12.011","article-title":"Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials","volume":"77","author":"Sayar","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178211_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11095-020-02790-3","article-title":"Sorafenib loaded inhalable polymeric nanocarriers against non-small cell lung cancer","volume":"37","author":"Shukla","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/0008-5472.CAN-20-2906","article-title":"Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential","volume":"81","author":"Strepkos","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178211_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178211_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cdd.2009.67","article-title":"Ubiquitin-independent p53 proteasomal degradation","volume":"17","author":"Tsvetkov","year":"2010","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2025.178211_bib44","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1038\/s41467-019-12606-7","article-title":"Genome-wide CRISPR\/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC","volume":"10","author":"Wei","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178211_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27144523","article-title":"Anticancer effects and mechanisms of berberine from medicinal herbs: an update review","volume":"27","author":"Xiong","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.178211_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110984","article-title":"Therapeutic effect of berberine on metabolic diseases: both pharmacological data and clinical evidence","volume":"133","author":"Xu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178211_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1500263","article-title":"The function of histone methyltransferase SETDB1 and its roles in liver cancer","volume":"12","author":"Zhang","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2025.178211_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9111660","article-title":"Role of ferroptosis in non-alcoholic fatty liver disease and its implications for therapeutic strategies","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178211_bib49","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41401-022-00981-9","article-title":"Sorafenib triggers ferroptosis via inhibition of HBXIP\/SCD axis in hepatocellular carcinoma","volume":"44","author":"Zhang","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2025.178211_bib50","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cellsig.2014.01.026","article-title":"Upregulation of HIF-2\u03b1 induced by sorafenib contributes to the resistance by activating the TGF-\u03b1\/EGFR pathway in hepatocellular carcinoma cells","volume":"26","author":"Zhao","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejphar.2025.178211_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1073713","article-title":"Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178211_bib52","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1111\/jcmm.15214","article-title":"Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib leading to inhibition of EMT in human lung cancer","volume":"24","author":"Zheng","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178211_bib53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2025.178211_bib54","article-title":"Apoptosis induction, a sharp edge of berberine to exert anti-cancer effects, focus on breast, lung, and liver cancer","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:35:18Z","timestamp":1779323718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925009653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":54,"alternative-id":["S0014299925009653"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178211","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Berberine sensitizes liver cancer cells to sorafenib by inducing SETDB1\/NQO1\/p53-dependent ferroptosis and genomic instability","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178211"}}